EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

EyeGate Pharmaceuticals, Inc.

271 Waverley Oaks Road
Suite 108
Waltham, MA 02452
United States
781-788-9043
http://www.eyegatepharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen FromPres, CEO & Director500kN/A1963
Dr. Barbara M. WirostkoChief Medical Officer322kN/A1966
Ms. Sarah RomanoChief Financial OfficerN/AN/AN/A
Dr. MaryJane Rafii Ph.D.ConsultantN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Corporate Governance

EyeGate Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.